Esophageal Carcinomas and Carcinomas of the Gastroesophageal Junction

(squamous cell carcinomas and adenocarcinomas)

Introduction

The EMA has approved pembrolizumab in combination with platinum- and fluoropyrimidine-based chemotherapy for the first-line treatment of locally advanced unresectable or metastatic oesophageal cancer in adults with PD L1-expressing tumors (CPS ≥ 10).
Furthermore, pembrolizumab in combination with trastuzumab and fluoropyrimidine- and platinum-based chemotherapy has been approved for the first-line treatment of locally advanced unresectable or metastatic HER2-positive adenocarcinoma of the gastroesophageal junction in adults with PD-L1-expressing tumors (CPS ≥ 1) and in combination with fluoropyrimidine- and platinum-based chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-negative adenocarcinoma of gastric or gastroesophageal junction in adults with PD-L1-expressing tumors (CPS ≥ 1).

As pathologists, we will therefore be conducting immunohistological testing of both squamous cell carcinomas and adenocarcinomas (all AEG types) for PD-L1 as necessary.

In October 2021, marketing authorization was also granted for nivolumab in combination with fluoropyrimidine- and platinum-based chemotherapy for first-line treatment of HER2‑negative advanced or metastatic adenocarcinoma of the gastroesophageal junction of the esophagus and the stomach in tumors expressing PD-L1 (CPS ≥5).¹

Two further authorizations have been granted since April 2022 for squamous cell carcinoma of the esophagus. The first of these relates to first-line treatment of unresectable advanced and recurrent or metastatic squamous cell carcinoma with nivolumab in combination with chemotherapy, while the second relates to therapy with nivolumab and ipilimumab as a first-line therapy for unresectable advanced and recurrent or metastatic squamous cell carcinoma. A TPS/TC ≥1% is required by both authorizations.

Scores

CPS

When interpreting immune cells, it is also important to remember that lymphocytes and macrophages are evaluated, although granulocytes and plasma cells on the other hand are excluded from the evaluation.

The cut-off is therefore set at CPS ≥10 for therapy with pembrolizumab in combination with platinum- or fluoropyrimidine-based chemotherapy in esophageal carcinomas – regardless of whether squamous cell carcinoma or adenocarcinoma – and in HER2-negative adenocarcinomas of the gastroesophageal junction. We apply a cut-off of CPS ≥5 for HER2-negative adenocarcinomas of the esophagus, the gastroesophageal junction, and the stomach that are to receive a therapy with nivolumab in combination with platinum- or fluoropyrimidine-based chemotherapy.

TPS/TC

Interpretation guidance for esophageal carcinoma

• Use a high magnification: Evaluation of PD-L1 staining may be challenging for squamous cell carcinomas, since keratin pearls, cornoid lamellae, and desmosis can all make interpretation more difficult, and can represent pitfalls resulting in a false-positive evaluation. High magnification helps here, especially for excluding cases of desmosis, which must not be evaluated as positive. Necrotic or apoptotic cells and cases of dyskeratosis are excluded from the evaluation.
• More than 100 carcinoma cells: We require more than 100 viable tumor cells, particularly for evaluation of the TPS/TC.
• Caution is advised with adenocarcinomas:For adenocarcinomas, large intracytoplasmic mucin vacuoles can also cause difficulties in evaluation, leading to situations where the cytoplasm border displaced to the cell’s periphery is misinterpreted as staining in the membrane.

PD-L1 prevalence in esophageal carcinoma

In the KN599 study (Kato et al., ESMO 2020)², a PD-L1 prevalence (calculated with the CPS and a cut-off of >=10) of 49–52% was determined for all esophageal histologies combined.

In current study data that include HER2-negative adenocarcinomas of the gastroesophageal junction and the esophagus, prevalence for nivolumab is found to be 60% relative to CPS ≥5³.

In accordance with the CheckMate 648 study, prevalence for both therapy regimens in relation to TPS/TC ≥1% lies at 50%.⁴

Test system validation/antibody selection in esophageal carcinoma

The publication of a harmonization study performed in Germany is not yet final. In terms of the study antibodies, it can be seen that, for the squamous cell carcinomas and AEG tumors investigated, as has already been shown with other entities, SP142 stains comparatively fewer tumor cells than the other antibodies. On the other hand, SP263 provides us with a stronger expression pattern overall.

Guidance for practice

Specific interpretation guidance for esophageal carcinoma

Support for interpretation is available from Agilent DAKO at the following two links: Agilent DAKO Interpretation Handbook (22C3) and Agilent DAKO Interpretation Handbook (28-8)

Please note the following:

• A least 100 carcinoma cells should be available for interpretation.
• Necrotic cells, plasma cells, and granulocytes are excluded from CPS and TPS/TC scoring.
• When evaluating esophageal cancer, a carcinoma in situ component is excluded from CPS scoring.

The following tables provide you with full details and guidance for interpreting the CPS score. (Agilent DAKO ⁵, page 24)

Interpretation guidance for CPS definition numerator

	Tumor cells	Immune cells	Other cells
Included in numerator	Convincing partial or complete linear membrane staining (at any intensity) of viable invasive tumor cells	Membrane and/or cytoplasmic* staining (at any intensity) of mononuclear inflammatory cells (MICs) within tumor nests and adjacent supporting stroma Lymphocytes (including lymphocyte aggregates) Macrophages ‡ Only MICs directly associated with the response to the tumor are scored.	Excluded
Excluded from numerator	Non-staining tumor cells Tumor cels with only cytoplasmic staining	Non-staining MICs MICs (including lymphoid aggregates) associated with ulcers, chronic cystitis, or other, non-tumor-associated processes MICs associated with carcinoma in situ MICs associated with benign structures neutrophil/eosinophil granulocytes and plasma cells	Carcinoma in situ normal/benign cells Stromal cells (including fibroblasts) Necrotic cells and/or cellular debris

* In MICs, membrane and cytoplasmic stainings often cannot be distinguished due to the high nucleus-plasma relation. For this reason, both membrane and cytoplasmic stained MICs are contained in the score.
† “Neighboring MICs” is the definition of cells that are inside the same 20x field as the tumor. However, MICs that are not directly associated with the reaction to the tumor should be ruled out.
‡ Macrophages and histiocytes are assigned to the same kind of cell.

Interpretation guidance for CPS definition denominator

	Tumor cells	Immune cells	Other cells
Included in denuminator	All viable invasive tumor cells	Excluded	Excluded
Excluded from denuminator	Any necrotic or non-viable tumor cells Dysplastic cells	All immune cells of any type	Carcinoma in situ normale/benign cells Stromal cells (including fibroblasts) necrotic cells and/or cellular debris

Literature

1. Gadgeel, S. et al. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer. Journal of Clinical Oncology 38, 1505–1517 (2020).
2. K. Kato et al. Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study | OncologyPRO. Annals of Oncology (2020) 31 (suppl_4) https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pembrolizumab-plus-chemotherapy-versus-chemotherapy-as-first-line-therapy-in-patients-with-advanced-esophageal-cancer-the-phase-3-keynote-590-study (2020).
3. Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. The Lancet 398, 27–40 (2021).
4. Doki, Y. et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. New England Journal of Medicine 386, 449–462 (2022).
5.  Agilent Technologies Inc. PD-L1 IHC 28-8 pharmDx Interpretation Manual–Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, and Esophageal Adenocarcinoma. PD-L1 IHC 28-8 pharmDx is CE-IVD marked for in vitro diagnostic use (2021).